Released Feb 27, 2018, after the close
10-K filed Feb 27, 2018, 58 days after period end · 0001232524-18-000018
Q4 2017 · 10-K
Revenue$436.40M$436.40M +10.0% vs Q4 2016+6.0% vs Q3 2017
Net Income$232.21M$232.21M +99.0% vs Q4 2016+265.5% vs Q3 2017
EPS Diluted$3.79$3.79 +98.4% vs Q4 2016+268.0% vs Q3 2017
Gross Profit$404,847,000+12.8%
Operating Incomederived$141,205,000−14.7%
Operating Cash Flowderived$204,559,000+13.2%
Free Cash Flowderived$195,681,000+9.1%
Margins · derived
Gross margin92.8%+2.3 pt vs Q4 2016
Operating margin32.4%−9.4 pt vs Q4 2016
Net margin53.2%+23.8 pt vs Q4 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2017 | Q4 2016 | Q4 2015 | Q4 2014 |
|---|---|---|---|---|
| Revenue | $436.40M | $396.62M | $340.88M | $328.14M |
| Net Income | $232.21M | $116.69M | $82.76M | $81.61M |
| EPS Diluted | $3.79 | $1.91 | $1.32 | $1.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR